APLT Applied Therapeutics Inc.

48.86
+0.57  (+1%)
Previous Close 48.29
Open 50
Price To Book 29.43
Market Cap 904,620,131
Shares 18,514,534
Volume 107,646
Short Ratio
Av. Daily Volume 175,420
Stock charts supplied by TradingView

NewsSee all news

  1. Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

    AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p<0.01) AT-007 was well-tolerated; no drug-related adverse events reported at any dose

  2. Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th

    NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq

  3. Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  4. Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist's Forum (CVCT)

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  5. Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiation announced September 4, 2019.
AT-001
Diabetic cardiomyopathy (DbCM)
Phase 2 data January 8, 2019 noted significant plasma galactitol reduction of ~50% (p<0.01). Full data to be presented at the Society for Inherited Metabolic Disorders Annual Meeting, April 26 – 29, 2020.
AT-007
Galactosemia

Latest News

  1. Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

    AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p<0.01) AT-007 was well-tolerated; no drug-related adverse events reported at any dose

  2. Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th

    NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq

  3. Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  4. Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist's Forum (CVCT)

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  5. Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  6. Applied Therapeutics Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today

  7. Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated

  8. Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

    NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  9. Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting

    NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in